For research use only. Not for therapeutic Use.
Gefitinib hydrochloride（Cat No.:I002387）is an oral, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC) and other EGFR-mutant cancers. It works by blocking the activation of EGFR, which is involved in promoting cancer cell growth and survival. Gefitinib is primarily used in patients with NSCLC harboring specific EGFR mutations, offering a targeted therapy approach. It is known for its relatively mild side effect profile compared to traditional chemotherapy, though common side effects include diarrhea, skin rashes, and liver enzyme abnormalities.
| Catalog Number | I002387 |
| CAS Number | 184475-55-6 |
| Synonyms | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;hydrochloride |
| Molecular Formula | C22H25Cl2FN4O3 |
| Purity | ≥95% |
| Target | Protein Tyrosine Kinase/RTK |
| Solubility | H2O: ＜ 8.8 mg/mL, DMSO: ≤ 0.23 mg/mL |
| Storage | Store at -20°C |
| IC50 | 37 nM (Tyr1173-NR6wtEGFR cells); 26 nM (Tyr1173 -NR6W cells) |
| IUPAC Name | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;hydrochloride |
| InChI | InChI=1S/C22H24ClFN4O3.ClH/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15;/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27);1H |
| InChIKey | QUINXWLATMJDQF-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4.Cl |
